Mereo Biopharma
Mereo Biopharma has two late-stage assets, seeks non-dilutive financing for alvelestat Phase 3 trials, and reports cash runway through 2027.
NASDAQ
Mereo BioPharma Group plc
MREO
1 article
$43M Market cap · 2026-09-03
NASDAQ
MREO
1 article
$43M Market cap · 2026-09-03
Mereo Biopharma has two late-stage assets, seeks non-dilutive financing for alvelestat Phase 3 trials, and reports cash runway through 2027.